ERS Genomics:
The global CRISPR/Cas9 licensing leader

ERS Genomics today announced a non-exclusive license agreement granting Otsuka Pharmaceutical access to ERS Genomics’ CRISPR/Cas9 #patent portfolio. Otsuka Pharmaceutical is using #CRISPR technology for research and development. Read more: https://t.co/ihFH6lNaB3

We're delighted to announce that Jon Kratochvil has joined ERS Genomics as VP for Business Development & Licensing for North America. Read the full announcement here: https://t.co/HsnRyOAu3Z

Researchers have used #CRISPR to model myeloid leukaemia progression. #CRISPRCas9 was used to alter genes responsible for making cells #malignant, enabling the identification of #therapeutic targets for early #disease stages. Read more @DrugTargetRev: https://t.co/BQcXWkloPj